Find all the latest information in acute myeloid leukemia, arranged by types, translocations, and mutations. Listed below are recently updated categories.
How do methylation regulatory gene mutations affect outcome in patients with ELN favorable-risk AML?
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to James Yu, AdventHealth...
Patterns of response to venetoclax + hypomethylating agents in IDH-mutated AML
Isocitrate dehydrogenase 1/2 (IDH1/2) mutations occur in around 20% of patients with acute myeloid leukemia (AML) and, as...
CPX-351 in patients with a high risk of mortality
The treatment of patients with acute myeloid leukemia (AML) who are older or have significant co-morbidities remains challenging and carries a high...
What has ASH 2020 taught us about advancing frontline chemotherapy in AML?
Increased understanding of the driving genetic and epigenetic factors of acute myeloid leukemia (AML) in recent years has...
How safe and efficacious is conditioning with radiolabeled anti-CD45 antibody 211-At-BC8-B10?
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Brenda Sandmaier, Fred Hutchinson...
Beat AML Master trial: can we use precision medicine to treat older patients with AML?
The Beat AML Master trial is an umbrella study which contains 11 sub-studies covering the most prominent subtypes...
How does cytogenetic risk affect outcome of allo-SCT in patients with FLT3+ NPM1– AML?
During the 2021 Transplantation & Cellular Therapy (TCT) Meetings Digital Experience, the AML Hub spoke to Arnon...
Highlights for MRD assessment in AML
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Lars Bullinger, Charité – Universitätsmedizin Berlin,...
Core binding factor
Epigenetic modifier mutations
Signaling pathway mutations
Transcription factor mutations
Tumor suppressor mutations